|
|
Article: EKR Therapeutics Closes $13M Series C And Acquires DepoDur.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Specialty pharmaceutical company EKR Therapeutics Inc. raised more than $13 million in a Series C financing, a portion of which it used to acquire the marketed pain product DepoDur (morphine sulfate extended-release liposome injection) from Pacira Pharmaceuticals Inc.
Stuart Levine, an EKR spokesman, said the $13 million in Series C funding is "additive" to cash the company had on hand. Including the current round, Cedar Knolls, N.J.-based EKR has raised more than $21 million since its founding in 2005.
A combination of existing and Series C funding was used to acquire exclusive marketing and distribution rights to DepoDur in the ...